What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
The scientist’s investigation covers issues in Internal medicine, Oncology, Breast cancer, Surgery and Chemotherapy.
His research links Gastroenterology with Internal medicine.
His Oncology research incorporates themes from Paclitaxel, Tumor-infiltrating lymphocytes, Proportional hazards model, Docetaxel and Biomarker.
His Breast cancer research includes elements of Adjuvant, Clinical trial and Metastasis.
His biological study spans a wide range of topics, including Cohort and Rituximab.
His work deals with themes such as Anthracycline, Regimen, Recurrence score, Molecular diagnostic techniques and Estrogen Metabolism, which intersect with Chemotherapy.
His most cited work include:
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 (1126 citations)
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer (745 citations)
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 (687 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Oncology, Breast cancer, Cancer and Chemotherapy.
His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Surgery.
Joseph A. Sparano works mostly in the field of Oncology, limiting it down to topics relating to Rituximab and, in certain cases, CHOP and Non-Hodgkin's lymphoma.
His Breast cancer study integrates concerns from other disciplines, such as Cancer research, Disease, Docetaxel and Hazard ratio.
His research in Cancer intersects with topics in Gynecology and Pathology.
His Chemotherapy study frequently draws connections between adjacent fields such as Regimen.
He most often published in these fields:
- Internal medicine (79.31%)
- Oncology (62.84%)
- Breast cancer (52.87%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (79.31%)
- Oncology (62.84%)
- Breast cancer (52.87%)
In recent papers he was focusing on the following fields of study:
Joseph A. Sparano mainly focuses on Internal medicine, Oncology, Breast cancer, Cancer and Chemotherapy.
His research in Metastatic breast cancer, Hazard ratio, Clinical trial, Chemotherapy regimen and Neutropenia are components of Internal medicine.
His research on Oncology also deals with topics like
- Disease which is related to area like Immune checkpoint,
- Early breast cancer which intersects with area such as 21 gene recurrence score.
Joseph A. Sparano has included themes like Stage, Metastasis and Proportional hazards model in his Breast cancer study.
His work deals with themes such as Biomarker, Eribulin, Paclitaxel and Doxorubicin, which intersect with Metastasis.
His study looks at the intersection of Chemotherapy and topics like Prospective cohort study with Adjuvant.
Between 2016 and 2021, his most popular works were:
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (685 citations)
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (293 citations)
- Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. (259 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Breast cancer
Joseph A. Sparano focuses on Internal medicine, Oncology, Breast cancer, Chemotherapy and Cancer.
His studies in Cyclophosphamide, Disease, Young adult, Adjuvant and Prospective cohort study are all subfields of Internal medicine research.
His Oncology study combines topics in areas such as Clinical trial, Metastatic breast cancer, Metastasis, Biomarker and Radiation therapy.
Joseph A. Sparano combines subjects such as Stage, Proportional hazards model and Hazard ratio with his study of Breast cancer.
His studies deal with areas such as Pertuzumab, Neoadjuvant therapy and Trastuzumab emtansine as well as Chemotherapy.
His work in Cancer addresses subjects such as Immunosuppression, which are connected to disciplines such as Lung cancer, Case fatality rate, Multivariate analysis, Malignancy and Anal cancer.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
